Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 open-label niraparib monotherapy in Japanese patients with advanced solid tumors
jRCT2080223855Phase 1Completed
- Sponsor
- Takeda
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of niraparib in Nonhematologic neoplasms (2 arms), sponsored by Takeda. Primary endpoints: Safety and tolerability of niraparib (primary analysis) and Pharmacokinetics of niraparib (primary analysis). Started Apr 2018; status: completed.
02
Drugs
niraparib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080223855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223855.